Indocyangreen Elimination in Cirrhosis and Acute Liver Failure

Indocyangreen (ICG)is totally biliary eliminated and corresponds to hepatocyte function and liver perfusion.

The ICG-clearance will be evaluated as a prognostic marker in liver disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Liver Failure Digestive System Diseases Fibrosis Hepatic Insufficiency Liver Cirrhosis Liver Diseases Liver Failure Liver Failure, Acute Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Heidelberg

Heidelberg, 69120, Germany

About this study

patients with acute liver failure or advanced liver disease will be studied. ICG-clearance will be correlated with established clinical scores and outcome.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

acute liver failure OR end-stage liver disease
normal hepatic perfusion by doppler ultrasound

Exclusion criteria

portal vein thrombosis
allergy to ICG or iodine
thyroid disease

Treatment and study plan

Indocyangreen (ICG) clearance

Procedure

Sponsors and collaborators

Lead sponsor

Heidelberg University

Other

Registry information

Official study title

Evaluation of the Indocyangreen Elimination as a Prognostic Marker in Decompensated Cirrhosis and Acute Liver Failure

Important dates

Study start: 2005
Primary completion: 2010
Study completion: 2010
First posted: Oct 27, 2005
Registry last updated: Oct 11, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting